Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01043-5
Abstract: B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and… read more here.
Keywords: multiple myeloma; bcma directed; infectious complications; directed therapies ... See more keywords
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01081-z
Abstract: Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo… read more here.
Keywords: prior bdt; bcma directed; adcs car; features associated ... See more keywords
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280241282115
Abstract: Objective: To review the pharmacology, efficacy, safety, dosing and administration, and relevance to patient care and clinical practice of B-cell maturation antigen (BCMA) directed immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies… read more here.
Keywords: multiple myeloma; treatment; bcma directed; directed immunotherapies ... See more keywords
Epigenetic Modifications As a Mechanism of Resistance to BCMA-Directed Immunotherapies in Multiple Myeloma: Insights from Multi-Omic Profiling
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198117
Abstract: Introduction Recent advancements in B-cell maturation antigen (BCMA)-directed immunotherapies, such as CAR T-cell therapy and bispecific T-cell engagers, have significantly improved treatment outcomes for Multiple Myeloma (MM). However, resistance to these therapies remains a substantial… read more here.
Keywords: bcma; treatment; methylation; resistance ... See more keywords
Steric Hindrance By APRIL in Binding of BCMA-Directed Bispecific Antibodies: A Novel Refractory Mechanism of BCMA-Directed Immunotherapies in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204524
Abstract: Multiple myeloma (MM) cells preferentially reside and grow in the bone marrow while activating osteoclasts (OCs). The aberrantly activated OCs induce bone lysis and support MM-cell growth and survival, leading to forming the vicious cycle… read more here.
Keywords: bcma; anti bcma; bcma directed; directed immunotherapies ... See more keywords
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2025015973
Abstract: Key Points • BsAbs are safe and effective in frail and older patients with MM.• Advanced age, worse PS, and higher comorbidity burden do not predict inferior outcomes with BsAbs in myeloma. read more here.
Keywords: receiving bcma; bcma directed; directed bispecific; outcomes frail ... See more keywords
Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e23309
Abstract: e23309 Background: BCMA-directed T-cell–engaging therapies have been introduced into clinical practice for the treatment of TCE RRMM. While efficacious, such treatments are associated with safety considerations such as cytokine release syndrome (CRS), immune effector cell-associated… read more here.
Keywords: directed cell; treatment; bcma directed; hospitalization ... See more keywords